Codexis Inc. (NASDAQ:CDXS) rose 2.5% during trading on Thursday . The stock traded as high as $4.15 and last traded at $4.12, with a volume of 87,317 shares changing hands. The stock had previously closed at $4.02.

CDXS has been the subject of several recent research reports. Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. HC Wainwright restated a “buy” rating on shares of Codexis in a report on Tuesday, May 10th.

The stock’s market capitalization is $168.05 million. The company’s 50 day moving average is $4.01 and its 200-day moving average is $3.78.

Codexis (NASDAQ:CDXS) last issued its earnings results on Monday, May 9th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $8 million for the quarter, compared to analysts’ expectations of $7.49 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.07) earnings per share. Analysts expect that Codexis Inc. will post ($0.25) EPS for the current year.

An institutional investor recently raised its position in Codexis stock. EAM Investors LLC increased its stake in shares of Codexis Inc. (NASDAQ:CDXS) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 407,255 shares of the company’s stock after buying an additional 1,604 shares during the period. EAM Investors LLC owned approximately 1.01% of Codexis worth $1,723,000 at the end of the most recent quarter.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.